Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous sonelokimab versus placebo in adults with moderate to severe hidradenitis suppurativa
NL-OMON60061Phase 3Completed
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Nov 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in hidradenitis suppurativa (HS) comparing Sonelokimab with Placebo (2 arms). Primary endpoint: Percentage of participants achieving HiSCR75 at Week 16. Started Nov 2024; status: completed.
02
Drugs
sonelokimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON60061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60061.